INTRODUCTION
In addition to its importance in the coagulation mechanism the Factor the interaction of platelets with the vessel wall (1) . The latter role was initially suggested by the observation of a prolonged bleeding time in patients with severe von Willebrand's disease (vWD) , and by the correction of the bleeding time in such patients after infusion of some FVIII-rich plasma fractions (2) . Furthermore, histological studies of biopsies of bleeding time sites in vWD patients showed an absence of platelet adhesion to vessel walls, which could be normalized by prior infusion of plasma (3, 4) . Finally, adhesion of platelets to de-endothelialized rabbit (5) or human (6) arterial tissue is dependent on the presence of FVIII in the tissues or in the circulating plasma.
A great deal ofinvestigation has been directed toward an understanding of the mechanism of platelet aggregation induced by the antibiotic ristocetin (1, 2, 7, 8) , which depends upon the presence of FVIII-related ristocetin cofactor activity (VIII:Rcf). In some patients with vWD, however, there is a lack of correlation between the bleeding time and VIII:Rcf levels (9, 10) . Furthermore, infusion of some VIII :Rcf-rich concentrates does not correct the prolonged bleeding time in patients with vWD despite normalization of plasma VIII:Rcf levels (11) . These observations suggest that the mechanism of Factor VIII-dependent ristocetininduced platelet aggregation may differ from the mechanism of Factor VIII-dependent platelet-vessel wall interaction.
Little attention has been paid to the observation that desialylated human FVIII is capable of aggregating platelets directly (12) (13) (14) . Because (17) . Gel-filtration was performed on a 5
x 80-cm column of Sepharose 6B (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) equilibrated with a buffer consisting of 0.02 M imidazole, 0.15 M NaCl, 0.01 M sodium citrate, 0.02 M EACA, pH 6.5. The void volume peak containing FVIII was concentrated by ultracentrifugation for 3.5 h at 220,000 g, as originally suggested by Thelin and Wagner (18) , and stored at4°C at concentrations of0.8-2.2 mg/ ml. FVIII from two patients with variant vWD was purified by cryoprecipitation in the presence of ethanol (16), which was followed by the steps previously outlined, with the following modifications: the bentonite absorption step was omitted, and a narrower (2.5 x 70 cm) Sepharose 6B column was used.
For experiments utilizing this material, normal FVIII was prepared in an identical fashion.
Fibrinogen was purified from citrated human plasma by the glycine precipitation method of Kazal et al. (19) (23) . Protein measurement was done by the method of Lowry et al. (24) .
Platelet aggregation, thromboxane measurement, and coagulation assays. Blood was collected into 1/9 vol of 3.2% sodium citrate and centrifuged at 230 g for 10 min at room temperature to obtain platelet-rich plasma (PRP). Fresh washed platelets (WP) were prepared as described by Walsh (25) and resuspended in Ca++-free Tyrode's buffer. Formalintreated platelets were prepared as described by Allain et al. (26) , and resuspended in Tyrode's buffer free of both Mg++ and Ca++. Platelet aggregation studies were carried out at a final platelet concentration of [3] [4] x 108 platelets/ml in a Payton dual channel aggregometer (Payton Associates, Inc., Buffalo, N. Y.) with 0.4-0.5 ml PRP or WP. ADP was obtained from the Sigma Chemical Co. (St. Louis, Mo.), epinephrine from Elkins-Sinn, Inc. (Cherry Hill, N. J.), collagen from Hormon-Chemie (Munich, Germany), and ristocetin from Lenau (Copenhagen, Denmark). When fibrinogen was added to WP, the final concentration was 0.3-0.7 mg/ml. To measure thromboxane B2, samples of PRP were removed from the aggregrometer cuvette 6 min after addition of the aggregating agent and were centrifuged at 15,000 g for 2 min. Thromboxane B2 was measured in the supernate as described by Lewy et al. (27) . VIII:C, FVIII-related antigen (VIII:Ag), and VIII:Rcf were assayed by standard methods (26, (28) (29) (30) (31) .
Radiolabeling of Factor VIII. Purified FVIII was tritium labeled at galactose residues, as described by Morell et al. (32) , omitting peroxidase. FVIII (1-1.5 mg/ml) was incubated with an approximately equal volume of galactose oxidase (80 U/mg FVIII) for 3 h at 37°C, after which 2-3 mCi [3H]-sodium borohydride (high specific activity, Amersham Corp., Arlington Heights, Ill.) was added per milliliter of reaction mixture and the mixture stirred for 30 min. The sample was passed through a 1.5 x 26-cm Sepharose 6B column equilibrated with 0.02 M Tris, 0.15 M NaCl, pH 7.3. The FVIII was concentrated to -1 mg/ml either against 20% polyethylene glycol 20 General aggregating properties ofASVIII. ASVIII produces aggregation of platelets in citrated PRP (Fig.  la) . Asialofibrinogen and asialoprothrombin (data not shown) neither aggregate PRP nor interfere with ASVIII-induced aggregation of PRP. ASVIII-induced platelet aggregation in PRP is accompanied by thromboxane formation (46 pmol/ml). In the presence of aspirin, only primary aggregation is seen and thromboxane formation is inhibited (0.72 pmol/ml). WP do Table II . In the final Sepharose 6B gel-filtration step of the preparation of patient FVIII void volume, VIII :Ag accounted for only 30% of the total, whereas 85% of the normal control VIII:Ag appeared in the void volume. Void volume fractions from the patients were pooled and concentrated and analyzed for sialic acid content. The FVIII in one patient had a normal sialic acid content, whereas in the second patient the sialic acid content was half normal (Table II) . Desialylated patient FVIII did not produce platelet aggregation even at final concentrations of 50-75 ,ug/ml. basis in binding to platelets (Fig. 4) . The specific activity of the [3H]ASVIII was the same as that of
[3H]FVIII exposed to the desialylating conditions in the absence of neuraminidase, which indicates that none of the tritium had been incorporated into sialic acid residues.
Binding of [3H]ASVIII to platelets in stirred PRP was complete within 3 min (Fig. 5a ). When binding was studied as a function of [3H]ASVIII concentration (Fig. 5b) (12) (13) (14) observed that desialylated human FVIII aggregated human platelets in PRP, but did not aggregate washed platelets unless fibrinogen was added; aggregation was inhibited by EDTA. The potential significance of ASVIII-platelet interactions has not been explored further. The data reported here demonstrate that ASVIII is a specific and potent platelet-aggregating agent, which apparently requires an intact platelet for full expression of its aggregating potency. The inability of ASVIII to aggregate BernardSoulier syndrome platelets, which are deficient in platelet membrane glycoprotein I (36) , suggests that The interaction of ASVIII with platelets shows both cellular and protein specificity. ASVIII binds to platelets, but not to lymphocytes or erythrocytes, whereas normal FVIII binds to platelets in only negligible amounts unless ristocetin is added, as has previously been shown by many investigators (8, (42) (43) (44) (45) (46) . ASVIII prepared from two vWD variants has no platelet aggregating activity, which indicates that removal ofnegative charge from the FVIII complex is insufficient to explain this activity. In addition, asialofibrinogen, asialoprothrombin, and other asialoproteins, as shown by us and others (14) , do not induce platelet aggregation. Finally, asialofibrinogen does not inhibit either ASVIII-induced platelet aggregation or ASVIII binding to platelets.
The precise mechanism whereby ASVIII binds to platelets is not clear. Ashwell and co-workers (20, 33, 47) have described a liver-membrane-associated pro- (52, 53) , and defects in carbohydrate structure is presently unclear.
The mechanism whereby FVIII exerts its hemostatic effects is still unknown. Although most in vivo studies of FVIII-platelet interactions use platelet aggregation as an end point, there is little or no evidence that FVIII is required for this phenomenon in vivo (3) (4) . To the contrary, there is persuasive evidence that FVIII, in some form, is essential for the interaction of platelets and the vascular subendothelium (5-6). Several recent articles have suggested an enhancing role for FVIII in platelet adhesion to collagen and in collagen-induced platelet aggregation (54) (55) (56) (57) . Our data demonstrate that ASVIII induces thromboxane synthesis and that even small amounts of ASVIII act synergistically with ADP and epinephrine, as well as with collagen, to promote platelet aggregation under conditions in which fully sialylated FVIII has no effect. The presence of even small amounts of ASVIII in the blood or in the subendothelium might enhance platelet adhesion to subendothelium and promote subsequent platelet aggregation. Since sialidases and sialyltransferases have been identified in platelets (58, 59 ) and other cells (60, 61) , as well as in circulating blood, the potential exists for the presence of ASVIII in vivo. Thus, in addition to its utility as a tool for the study of FVIII-platelet interactions in the absence of ristocetin, ASVIII may be a physiologically important mediator of the hemostatic effects of Factor VIII.
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